Essra Youssef
Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK
Youssef, Essra; Kirkdale, Charlotte L.; Wright, David J.; Guchelaar, Henk Jan; Thornley, Tracey
Authors
Charlotte L. Kirkdale
David J. Wright
Henk Jan Guchelaar
TRACEY THORNLEY Tracey.Thornley1@nottingham.ac.uk
Professor of Health Policy
Abstract
Aims: Pharmacogenetics (PGx) in the UK is currently implemented in secondary care for a small group of high-risk medicines. However, most prescribing takes place in primary care, with a large group of medicines influenced by commonly occurring genetic variations. The goal of this study is to quantitatively estimate the volumes of medicines impacted by implementation of a population-level, pre-emptive pharmacogenetic screening programme for nine genes related to medicines frequently dispensed in primary care in 2019.
Methods: A large community pharmacy database was analysed to estimate the national incidence of first prescriptions for 56 PGx drugs used in the UK for the period 1 January–31 December 2019. These estimated prescription volumes were combined with phenotype frequency data to estimate the occurrence of actionable drug–gene interactions (DGI) in daily practice in community pharmacies.
Results: In between 19.1 and 21.1% (n = 5 233 353–5 780 595) of all new prescriptions for 56 drugs (n = 27 411 288 new prescriptions/year), an actionable drug–gene interaction (DGI) was present according to the guidelines of the Dutch Pharmacogenetics Working Group and/or the Clinical Pharmacogenetics Implementation Consortium. In these cases, the DGI would result in either increased monitoring, guarding against a maximum ceiling dose or an optional or immediate drug/dose change. An immediate dose adjustment or change in drug regimen accounted for 8.6–9.1% (n = 2 354 058–2 500 283) of these prescriptions.
Conclusions: Actionable drug–gene interactions frequently occur in UK primary care, with a large opportunity to optimise prescribing.
Citation
Youssef, E., Kirkdale, C. L., Wright, D. J., Guchelaar, H. J., & Thornley, T. (2021). Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK. British Journal of Clinical Pharmacology, 87(7), 2907-2925. https://doi.org/10.1111/bcp.14704
Journal Article Type | Article |
---|---|
Acceptance Date | Dec 7, 2020 |
Online Publication Date | Jan 19, 2021 |
Publication Date | 2021-07 |
Deposit Date | Jan 14, 2023 |
Publicly Available Date | Jan 17, 2023 |
Journal | British Journal of Clinical Pharmacology |
Print ISSN | 0306-5251 |
Electronic ISSN | 1365-2125 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 87 |
Issue | 7 |
Pages | 2907-2925 |
DOI | https://doi.org/10.1111/bcp.14704 |
Public URL | https://nottingham-repository.worktribe.com/output/15939772 |
Publisher URL | https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14704 |
Files
Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK
(1.7 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc-nd/4.0/
You might also like
The pharmacy care plan service: Evaluation and estimate of cost-effectiveness
(2018)
Journal Article
Survivor perspectives on the role of the community pharmacist in breast cancer services
(2018)
Journal Article